The utility of monitoring carcinoembyronic antigen during systemic therapy for advanced colorectal cancer

Jean L Grem, Seth M. Steinberg, Alice P. Chen, Manette McAtee, Ellen Cullen, J. Michael Hamilton, Carmen J. Allegra

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

To determine if pre-treatment serum carcino-embryonic antigen (CEA) levels or changes in CEA values during treatment have prognostic value, we reviewed five prior fluorouracil/leucovorin-based trials and identified 125 colorectal cancer patients with no prior chemotherapy for metastatic disease in whom CEA values were available. Although pre-treatment serum CEA values did not predict for clinical response or time to progression, serial monitoring of CEA appeared to be useful in patients with an elevated pretreatment CEA, particularly when a decrease in CEA occurred in concert with radiographic evidence of disease response. The CEA nadir was a strong prognostic variable with respect to time to disease progression. A consistent rise in CEA values over the minimum value signals the need for radiographic reassessment of the patient's disease status to rule out disease progression.

Original languageEnglish (US)
Pages (from-to)559-567
Number of pages9
JournalOncology reports
Volume5
Issue number3
StatePublished - May 7 1998

Fingerprint

Colorectal Neoplasms
Antigens
Therapeutics
Disease Progression
Leucovorin
Serum
Fluorouracil
Drug Therapy

Keywords

  • Carcinoembryonic antigen
  • Colon cancer
  • Prognostic indicators
  • Rectal cancer
  • Tumor markers

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Grem, J. L., Steinberg, S. M., Chen, A. P., McAtee, M., Cullen, E., Michael Hamilton, J., & Allegra, C. J. (1998). The utility of monitoring carcinoembyronic antigen during systemic therapy for advanced colorectal cancer. Oncology reports, 5(3), 559-567.

The utility of monitoring carcinoembyronic antigen during systemic therapy for advanced colorectal cancer. / Grem, Jean L; Steinberg, Seth M.; Chen, Alice P.; McAtee, Manette; Cullen, Ellen; Michael Hamilton, J.; Allegra, Carmen J.

In: Oncology reports, Vol. 5, No. 3, 07.05.1998, p. 559-567.

Research output: Contribution to journalArticle

Grem, JL, Steinberg, SM, Chen, AP, McAtee, M, Cullen, E, Michael Hamilton, J & Allegra, CJ 1998, 'The utility of monitoring carcinoembyronic antigen during systemic therapy for advanced colorectal cancer', Oncology reports, vol. 5, no. 3, pp. 559-567.
Grem JL, Steinberg SM, Chen AP, McAtee M, Cullen E, Michael Hamilton J et al. The utility of monitoring carcinoembyronic antigen during systemic therapy for advanced colorectal cancer. Oncology reports. 1998 May 7;5(3):559-567.
Grem, Jean L ; Steinberg, Seth M. ; Chen, Alice P. ; McAtee, Manette ; Cullen, Ellen ; Michael Hamilton, J. ; Allegra, Carmen J. / The utility of monitoring carcinoembyronic antigen during systemic therapy for advanced colorectal cancer. In: Oncology reports. 1998 ; Vol. 5, No. 3. pp. 559-567.
@article{b8a2edcf00a344d9ba830524d4a63fea,
title = "The utility of monitoring carcinoembyronic antigen during systemic therapy for advanced colorectal cancer",
abstract = "To determine if pre-treatment serum carcino-embryonic antigen (CEA) levels or changes in CEA values during treatment have prognostic value, we reviewed five prior fluorouracil/leucovorin-based trials and identified 125 colorectal cancer patients with no prior chemotherapy for metastatic disease in whom CEA values were available. Although pre-treatment serum CEA values did not predict for clinical response or time to progression, serial monitoring of CEA appeared to be useful in patients with an elevated pretreatment CEA, particularly when a decrease in CEA occurred in concert with radiographic evidence of disease response. The CEA nadir was a strong prognostic variable with respect to time to disease progression. A consistent rise in CEA values over the minimum value signals the need for radiographic reassessment of the patient's disease status to rule out disease progression.",
keywords = "Carcinoembryonic antigen, Colon cancer, Prognostic indicators, Rectal cancer, Tumor markers",
author = "Grem, {Jean L} and Steinberg, {Seth M.} and Chen, {Alice P.} and Manette McAtee and Ellen Cullen and {Michael Hamilton}, J. and Allegra, {Carmen J.}",
year = "1998",
month = "5",
day = "7",
language = "English (US)",
volume = "5",
pages = "559--567",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "3",

}

TY - JOUR

T1 - The utility of monitoring carcinoembyronic antigen during systemic therapy for advanced colorectal cancer

AU - Grem, Jean L

AU - Steinberg, Seth M.

AU - Chen, Alice P.

AU - McAtee, Manette

AU - Cullen, Ellen

AU - Michael Hamilton, J.

AU - Allegra, Carmen J.

PY - 1998/5/7

Y1 - 1998/5/7

N2 - To determine if pre-treatment serum carcino-embryonic antigen (CEA) levels or changes in CEA values during treatment have prognostic value, we reviewed five prior fluorouracil/leucovorin-based trials and identified 125 colorectal cancer patients with no prior chemotherapy for metastatic disease in whom CEA values were available. Although pre-treatment serum CEA values did not predict for clinical response or time to progression, serial monitoring of CEA appeared to be useful in patients with an elevated pretreatment CEA, particularly when a decrease in CEA occurred in concert with radiographic evidence of disease response. The CEA nadir was a strong prognostic variable with respect to time to disease progression. A consistent rise in CEA values over the minimum value signals the need for radiographic reassessment of the patient's disease status to rule out disease progression.

AB - To determine if pre-treatment serum carcino-embryonic antigen (CEA) levels or changes in CEA values during treatment have prognostic value, we reviewed five prior fluorouracil/leucovorin-based trials and identified 125 colorectal cancer patients with no prior chemotherapy for metastatic disease in whom CEA values were available. Although pre-treatment serum CEA values did not predict for clinical response or time to progression, serial monitoring of CEA appeared to be useful in patients with an elevated pretreatment CEA, particularly when a decrease in CEA occurred in concert with radiographic evidence of disease response. The CEA nadir was a strong prognostic variable with respect to time to disease progression. A consistent rise in CEA values over the minimum value signals the need for radiographic reassessment of the patient's disease status to rule out disease progression.

KW - Carcinoembryonic antigen

KW - Colon cancer

KW - Prognostic indicators

KW - Rectal cancer

KW - Tumor markers

UR - http://www.scopus.com/inward/record.url?scp=0031959151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031959151&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 559

EP - 567

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 3

ER -